Kornimate/medical-research-clean huggingface dataset:
medications for stopping cocaine dependence and preventing relapse

Conditions: Cocaine Abuse; Cocaine-Related Disorders

Summary: cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. the purpose of this study is to identify subpopulations and baseline conditions that are most responsive to treatment for cocaine dependent individuals.

cocaine is a strong central nervous system stimulant that is widely abused throughout the united sates. due to its widespread use, it is important to develop an effective treatment for cocaine dependence. motivational interviewing (mi) is often effective when combined with drug treatment. baseline condition (e.g., abstinence status) and population type (e.g., ethnicity and gender) often affect how an individual responds to treatment for drug dependence. the purpose of this study is to determine the influence of baseline status and population type on treatment response in cocaine dependent individuals. in addition, this study will examine how various cocaine abuse medications target different neuronal systems, withdrawal symptoms, and relapse to drug use. this study will take place in two phases. phase i will last 4 weeks; participants will receive mi and undergo contingency-based urine tests in order to achieve the desired baseline condition. phase ii will last 12 weeks. participants in phase ii will be randomly assigned to receive one of four treatments: 1) 50 mg naltrexone, 2) 800/200 mg levodopa/carbidopa, 3) 400 mg modafinil, or 4) placebo. during phase ii, all participants will receive psychotherapy and contingency management. participants will complete urine drug screening tests 3 times each week. follow-up study visits will occur between 3 and 6 months following week 12, and will include objective and self-reported drug use.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for current cocaine dependence exclusion criteria: * meet diagnostic criteria for other serious psychiatric symptoms and/or disorders that would interfere with participation in the treatment study (e.g., psychosis; mania; suicidal/ homicidal ideation) including other forms of drug dependence, nicotine and cannabis excepted. * medical conditions contraindicating naltrexone therapy (e.g., past history of opioid use in the 30 days prior to study entry or significant hepatocellular injury) * medical conditions contraindicating modafinil therapy (e.g., hypertension, seizures, arrhythmia, or coronary artery disease) * medical conditions contraindicating levodopa/carbidopa therapy (e.g., severe pulmonary/cardiovascular disease, narrow angle glaucoma, melanoma, history of peptic ulcer, or renal function impairment) * requires certain medications * current or recent treatment for substance use or other psychiatric condition * on parole or probation that requires reports of drug use to officers of the court * pending incarceration * pregnant or breastfeeding * unable to read, write, or speak english * plans to leave the study area within 3 months of study entry

Keywords: cocaine cocaine addiction cocaine abuse relapse prevention
anticipated and perceived benefits following hepatitis c treatment

Conditions: Hepatitis C; Hepatitis C, Chronic

Summary: the study is both qualitative and quantitative, gathering patient's perceptions of hcv treatment benefits before and after hcv treatment by administering surveys and conducting in-depth qualitative patient interviews. the study seeks to understand all anticipated and actual benefits patients perceive before and after viral eradication.

this study employs a mixed methods (qualitative and quantitative) pre-post study design utilizing in-depth qualitative interviews and patient reported outcome surveys. pre-treatment surveys and interviews will be conducted before hcv therapy commences to understand all potential psychological, social, physical and medical consequences perceived to be related to hcv and the patients' anticipation (hope for) of improvements in these factors after viral eradication. post-treatment surveys and interviews will occur 4 to 8 months after treatment ends to examine long-term treatment benefits, i.e., changes in hcv-related factors, such as symptoms, functioning, and health status.

Eligibility criteria:
inclusion criteria: * age 21 or older * english-speaking * any genotype * any treatment duration (e.g. 8, 12, or 24 weeks) * has been written a prescription for a sofosbuvir (sof)-containing regimen. exclusion criteria: * currently listed for liver transplant; post-liver transplant

Keywords: hepatitis c patient-reported outcomes daa treatment qualitative mixed methods
chinese medicine neuroaid efficacy on stroke recovery

Conditions: Cerebral Infarction; Stroke

Summary: chimes is a double blind, placebo controlled, randomized, multicenter study to test the hypothesis that neuroaid is superior to placebo in reducing neurological deficit and improving functional outcome in patients with cerebral infarction of an intermediate range of severity.

stroke is a major cause of death and disability. previous clinical studies performed in china have shown that neuroaid increase stroke patients'recovery in terms of neurological disability and functional outcome{chen et al,2009}and thus may be beneficial as part of a post-stroke rehabilitation programme. in the chimes study,we seek to test the hypothesis that neuroaid is superior to a placebo in reducing neurological deficit and improving functional outcome in patients recruited within 72 h after the ischemic stroke with intermediate range of severity {6\<_nihss\<_14}.more details of the study protocol have recently been published {venketasubramanian et al,2009}.

Eligibility criteria:
inclusion criteria: * subject is aged 18 years old and above (for singapore 21 years and above as this is the legal age of consent) * subject is on anti-platelet therapy * subject is presented a pre-stroke modified rankin scale inferior or equal to 1 * female subject is eligible to participate in the trial if she is of non-childbearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post menopausal) * subject or his/her legally acceptable representative is willing to provide written informed consent * subject is presented with cerebral infarction with compatible imaging at computed tomography (ct) scan or magnetic resonance imaging (mri) * time window is less than 72 hours after symptoms onset * subject with cerebral infarction with intermediate severity range: 6 ≤ nihss ≤ 14 exclusion criteria: * subjects deemed unstable by investigator after thrombolysis treatment * subject has evidence of intra-cerebral hemorrhage on brain ct scan or mri * subject has a rapidly improving neurological deficit * subject has definite indication for full-dose or long-term anticoagulation therapy * subject has other significant non-ischemic brain lesion which could affect function disability * subject has co-existing systemic diseases: terminal cancer, renal failure (creatinine \> 200 μmol/l, if known), cirrhosis, severe dementia or psychosis * subject has participated in another clinical trial within the last three months

Keywords: stroke cerebral infarct recovery double blind randomized placebo traditional chinese medicine neuroaid
comparison of metformin and pioglitazone in regulating menstrual irregularities and hyperandrogenism

Conditions: Menstrual Irregularities; Hyperandrogenism

Summary: to compare metformin with pioglitazone in improving menstrual irregularities and hyperandrogenism in women with pcos so that an alternate and better treatment option will be available for hyperinsulinemia in pcos patients.

this study will be a prospective, randomized, open label, multicentre study. it will be carried out in outpatients department of obstetrics and gynecology, at the dow university of hospital and mamji hospital karachi. the study period will be of 6 months. polycystic ovarian syndrome pcos constitute most common endocrinopathy present in 4-7% women of reproductive age. rotterdam criteria, diagnosis of pcos require two of the three features: oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries by u/s and the absence of other endocrine conditions such as hypothyroidism, cushing syndrome, congenital adrenal hyperplasia, or hyperprolactinemia. insulin resistance and hyperinsulinemia may play a key role in pathogenesis of this syndrome by deregulating lh secretion at central level and increased stimulation of cytochrome p450 in ovary, hyperinsulinemia also decreases the circulating concentration of shbg and contribute to greater concentration of free androgens in blood, cut off of insulin level for insulin resistance in pakistani population is 9.25u/ml. on basis of evidence, insulin sensitizing agents has been recently proposed as a useful treatment option in women with pcos, which by reducing insulin resistance and hyperinsulinemia, reduce the insulin driven ovarian and adrenal hyperandrogenism usually restoring normal lh and fsh secretion and ovulatory cycles.

Eligibility criteria:
inclusion criteria: 1. women of age 18-40 with primary or secondary infertility. 2. polycystic ovarian syndrome daignosed using rotterdam criteria. 3. not taken any medication before for pcos. exclusion criteria: 1. women having type 1 or type 2 diabetes mellitus. 2. abnormal kidney or liver function. 3. hypertension or heart disease. 4. gonadotrophin induction or ovarian drilling before will not be included in this study.

Keywords: pco metformin
cortisol response to low dose cosyntropin stimulation test in the late afternoon

Conditions: Adrenal Insufficiency

Summary: previous study showed that afternoon cosyntropin testing was associated with a sevenfold increased likelihood of failing the 1μg test. however, in that study, investigators used a 20.3 cm plastic tube, which might have led to uncompleted cosyntropin delivery. in ther current study investigators will study afternoon 1μg cosyntropin cortisol stimulation using a short 2.5 cm tube.

in earlier studies investigators claimed that subnormal cortisol response using plastic tubes might result from cosyntropin adherence to the tube and loss of the delivered dosage. it was shown that 21.6-58.6% of acth dosage had not been recovered when pushed through 20.3 cm plastic tube, and loss of acth may be up to 70% when cosyntropin was delivered through a plastic 30 cm scalp vein set. moreover, it was previously shown that afternoon cosyntropin testing was associated with a sevenfold increased likelihood of failing the 1μg test. however, in that study, investigators used a 20.3 cm plastic tube, which might have led to uncompleted cosyntropin delivery. in ther current study investigators will study afternoon 1μg cosyntropin cortisol stimulation using a short 2.5 cm tube.

Eligibility criteria:
inclusion criteria: healthy volunteers exclusion criteria: clinical suspicion of hypoadrenalism medical condition or treatment that might alter blood cortisol levels pregnancy

Keywords: cosyntropin stimulation test low-dose
a study to learn about the study medicine called tafamidis 61mg in people diagnosed with transthyretin amyloid cardiomyopathy (attr-cm)

Conditions: Transthyretin Amyloid Cardiomyopathy

Summary: the purpose of this clinical trial is to learn about the effects of the study medicine (called tafamidis 61milligrams (mg)) for the potential treatment of transthyretin amyloid cardiomyopathy (attr-cm). this study is seeking participants who were prescribed tafamidis 61mg after being diagnosed with attr-cm and have taken tafamidis 61mg at least once. we will examine the experiences of people receiving the study medicine. this will help us determine if the study medicine is safe and effective.


Eligibility criteria:
inclusion criteria: * age ≥19 years * patients diagnosed with attr-cm (attrwt and attrv) with tissue biopsy or nuclear scintigraphy * patients who was prescribed tafamidis 61mg after being diagnosed with attr-cm and have taken tafamidis 61mg at least once. exclusion criteria: * presence of other amyloidosis
radiofrequency of breast cancers in non surgical patients

Conditions: Breast Cancer

Summary: to treat breast tumors in non surgical patients with percutaneous technique (radiofrequency). prospective evaluation of treatment efficiency and tolerance based on clinical and radiological evaluation


Eligibility criteria:
inclusion criteria: * patients more than 70 years old * breast tumors with estrogen receptors * non surgical patients * life expectancy more than 6 months exclusion criteria: * presence of a pace maker * tumors measuring more than 30 mm on ultrasound evaluation, located less than 10 mm from skin, nipple, or pectoral muscle * coagulation disorders * contra indications to magnetic resonance imaging or computed tomography with contrast medium injection * non visible lesions on magnetic resonance imaging or computed tomography with contrast medium injection

Keywords: radiofrequency percutaneous technique breast cancer tolerance
investigation of the effect of motor control exercises in patients undergoing rotator cuff surgery

Conditions: Rotator Cuff Tears

Summary: the aim of the study is to examine the effect of motor control exercises given through telerehabilitation on shoulder function and quality of life in patients undergoing rotator cuff surgery.

treatment of rotator cuff tears can be conservative or surgical. the aim of rehabilitation postoperative period, is to reduce pain, increase joint range of motion (rom), and enable the patient to return to normal functional activities as soon as possible while preventing the repaired tissue from tearing again. motor control training based on motor control theory reorganizes the cerebral cortex. in people with shoulder pain, a scapulothoracic posture retraining program reduces shoulder pain and improves scapulothoracic movement and muscle activation patterns and shoulder function. therefore, rehabilitation should include correct positioning of the scapulothoracic joint through active muscle activation (motor control training) and retraining. however, the evidence is still limited and the effect of motor control exercises is not yet fully understood. over the last 15 years, telerehabilitation in the broader field of telehealth has been used to help patients in rural areas improve healthcare and access services to reduce cost and transportation issues. studies on the upper extremity have also begun to increase in recent years. the aim of the study is to examine the effect of motor control exercises given through telerehabilitation on shoulder function and quality of life in patients undergoing rotator cuff surgery.

Eligibility criteria:
inclusion criteria: * undergone rotator cuff surgery * being 18 years of age * agree to participate in the study, * allowed early rehabilitation after surgery, * can speak and understand turkish * can make video conferences and phone calls. exclusion criteria: * have had previous surgery on the affected shoulder, * have neurological deficits and motor control disorders, * have systemic rheumatological disease, * have developed any complications that may affect rehabilitation in the shoulder, * have had revision surgery on the affected shoulder.

Keywords: rotator cuff surgery telerehabilitation motor control
relugolix pregnancy registry: an observational study of the safety of relugolix-containing therapy exposure in pregnant women and their offspring

Conditions: Pregnancy Related; Pregnancy Complications; Pregnancy, High Risk

Summary: the relugolix pregnancy registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. data will be collected from enrolled pregnant women and the healthcare providers (hcps) involved in their care or the care of their infants, if applicable.

the outcomes of interest include major congenital malformation (mcm; primary outcome), minor congenital malformation, spontaneous abortion (sab), stillbirth, elective termination, small for gestational age (sga), preterm birth, postnatal growth deficiency, and infant developmental deficiency. pregnancy outcomes will be assessed throughout pregnancy, with data collection occurring at enrollment, the end of the second trimester, and pregnancy outcome. infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery. enrolled pregnant women and the healthcare providers (hcps) involved in their care or the care of their infants, if applicable, will serve as data reporters to the registry. the registry is strictly observational; the schedule of office visits and all treatment regimens will be determined by hcps. only data that are documented in patients' medical records during the course of medical care will be collected. no additional laboratory tests or hcp assessments will be required as part of this registry.

Eligibility criteria:
inclusion criteria: * woman of any age * currently or recently pregnant * consent to participate * authorization for her hcp(s) to provide data to the registry cohort 1 * exposure to at least one dose of relugolix-containing therapy at any time during pregnancy cohort 2 * diagnosis of a condition for which relugolix-containing therapy may be prescribed and who are not exposed to relugolix containing therapy at any time during pregnancy exclusion criteria: the following will be eligible for enrollment, included in supplementary analyses, but excluded from the analysis population: * occurrence of pregnancy outcome prior to first contact with the registry coordination center (retrospectively enrolled) * exposure to known teratogens and/or investigational medications during pregnancy * lost to follow-up

Keywords: relugolix uterine fibroids endometriosis pregnancy
use of telemedicine to address 'off target' symptoms in psoriatic arthritis (psa)

Conditions: Psoriatic Arthritis

Summary: this will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (psa).

the proposed trial will be embedded within clinical care. this is a 2-year interventional trial that will enroll patients with active psoriatic arthritis despite stable therapy among three centers (the university of pennsylvania, university of utah, and university of oxford). the intervention employs psowelltm, a program that trains clinicians to utilize motivational interviewing to help patients set goals and make lifestyle/behavior changes for holistic management of psoriasis.

Eligibility criteria:
inclusion criteria: * population: patients with psoriatic arthritis * age 18-89. * active symptoms of psa as defined by a psa impact of disease (psaid) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10). * patients should be stable on therapy (i.e., not planning to switch therapy at the current visit). * meet caspar criteria. * provision of signed and dated informed consent form. * willingness to comply with all study procedures and availability for duration of the study. * has access to a mobile phone or other mobile device. exclusion criteria: * inability to provide informed consent. * plan to change systemic treatment for psoriasis or psa in the next 4-8 weeks. * psaid score ≤4
thermographic images as an objective method for assessing the efficacy of steroidal epidural injections

Conditions: Spinal Stenosis

Summary: spinal stenosis is a prevalent diagnosis, which is handled in a heterogeneous manner by clinicians. moreover, when using steroidal epidural injections, successful treatment is currently defined as the satisfaction of the patient from the treatments, a subjective and non-quantifiable indicator. in this experiment, the investigators aim to evaluate thermographic images as an objective method for assessing the efficacy of steroidal epidural injections, the most common invasive treatment for pain associated with spinal stenosis


Eligibility criteria:
inclusion criteria: * signed a valid, irb/ec-approved informed consent form * 18 years of age or older when written informed consent is obtained * diagnosis of spinal stenosis by mri or ct imaging exclusion criteria: * sensitivity to local anesthetics * skin infection at the site of needle insertion * had evidence of a peripheral neuropathy * had clinical signs of peripheral vascular disease * patient is pregnant * clinical diagnosis of blood clotting disorder * tumor or infection at spine as demonstrate at mri unbalanced cardiac insufficiency, hypertension \& diabetes cataract stomach ulcer
efficacy and safety study of ulipristal acetate in females with anemia associated with uterine leiomyoma

Conditions: Leiomyomas

Summary: the purpose of this study is to determine whether ulipristal acetate is effective in the treatment of females with anemia associated with uterine leiomyomas. the safety of this product will also be evaluated.

this is a randomized, placebo controlled, multicenter study with parallel groups in order to evaluate the efficacy and safety of ulipristal acetate in female subjects with anemia associated with uterine leiomyomas. the objective of this study is to determine if daily ulipristal acetate with iron is more effective than iron alone.

Eligibility criteria:
inclusion criteria: * is a pre-menopausal female, 18 - 50 years; * has documented leiomyoma(s); * has leiomyoma-related anemia; * has an endometrial biopsy within the screening period prior to the first dose of the test article which shows no endometrial hyperplasia; * is willing and able to provide written informed consent and authorization to disclose protected health information. exclusion criteria: * has a history of uterine surgery that would interfere with the study; * has a condition requiring immediate or intermittent blood transfusions; * has a known coagulation disorder; * has a history of uterine, cervix, ovarian, or breast cancer; * has used a selective progesterone receptor modulator or a gonadotrophin releasing hormone agonist in previous 6 months; * has received blood transfusion within 8 weeks before the screening visit; * has abnormal liver functions; * is pregnant.

Keywords: leiomyomas